应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
06990 科伦博泰生物-B
休市中 07-05 16:08:07
163.400
+11.500
+7.57%
最高
163.900
最低
149.700
成交量
35.80万
今开
157.700
昨收
151.900
日振幅
9.35%
总市值
364.13亿
流通市值
212.87亿
总股本
2.23亿
成交额
5,666万
换手率
0.27%
流通股本
1.30亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
科伦博泰生物-B(06990):认购结构性存款
智通财经 · 07-05 20:37
科伦博泰生物-B(06990):认购结构性存款
港股收盘(07.05) | 恒指收跌1.27% 科技股、汽车股普遍承压 医药股午后拉升
智通财经 · 07-05 16:40
港股收盘(07.05) | 恒指收跌1.27% 科技股、汽车股普遍承压 医药股午后拉升
港股异动 | 科伦博泰生物-B(06990)现涨超7% 公司携手默沙东出海 机构称核心产品商业化在即
智通财经 · 07-05 15:49
港股异动 | 科伦博泰生物-B(06990)现涨超7% 公司携手默沙东出海 机构称核心产品商业化在即
“体重管理年”实施方案出台,港股创新药ETF(159567)跟踪指数拉升翻红,泰格医药、绿叶制药、科伦博泰生物-B领涨。
界面有连云 · 07-05 10:18
“体重管理年”实施方案出台,港股创新药ETF(159567)跟踪指数拉升翻红,泰格医药、绿叶制药、科伦博泰生物-B领涨。
科伦博泰生物-B(06990)上涨5.07%,报159.6元/股
金融界 · 07-05 09:50
科伦博泰生物-B(06990)上涨5.07%,报159.6元/股
科伦博泰生物-B(06990)股价上升5.003%,现价港币$159.5
阿斯达克财经 · 07-05 09:50
科伦博泰生物-B(06990)股价上升5.003%,现价港币$159.5
科伦博泰生物-B07月04日获主力加仓482万元 环比增加760.71%
自选股智能写手 · 07-04 16:16
科伦博泰生物-B07月04日获主力加仓482万元 环比增加760.71%
科伦博泰生物-B(06990)下跌5.06%,报150.0元/股
金融界 · 07-03 09:52
科伦博泰生物-B(06990)下跌5.06%,报150.0元/股
科伦博泰生物-B(06990)下跌5.85%,报156.1元/股
金融界 · 07-02
科伦博泰生物-B(06990)下跌5.85%,报156.1元/股
科伦博泰生物-B(06990)拟以624万元向科伦药业(002422.SZ)附属收购一系列设备
智通财经 · 06-28
科伦博泰生物-B(06990)拟以624万元向科伦药业(002422.SZ)附属收购一系列设备
科伦博泰生物-B(06990)下跌5.19%,报151.5元/股
金融界 · 06-28
科伦博泰生物-B(06990)下跌5.19%,报151.5元/股
科伦博泰生物-B(06990.HK)认购1亿元理财产品
格隆汇资讯 · 06-27
科伦博泰生物-B(06990.HK)认购1亿元理财产品
科伦博泰生物-B(06990)合共认购2.2亿元兴业银行理财产品
智通财经 · 06-27
科伦博泰生物-B(06990)合共认购2.2亿元兴业银行理财产品
科伦博泰生物-B(06990)下跌5.17%,报157.9元/股
金融界 · 06-27
科伦博泰生物-B(06990)下跌5.17%,报157.9元/股
科伦博泰生物-B(06990)下跌5.26%,报162.0元/股
金融界 · 06-25
科伦博泰生物-B(06990)下跌5.26%,报162.0元/股
科伦博泰生物-B(06990)ADC征途星辰大海,携手跨国龙头进军国际市场
国盛证券 · 06-24
科伦博泰生物-B(06990)ADC征途星辰大海,携手跨国龙头进军国际市场
【券商聚焦】华泰证券首予科伦博泰生物-B(06990)“买入”评级 指其与MNC合作临床打开海外商业化空间
金吾财讯 · 06-21
【券商聚焦】华泰证券首予科伦博泰生物-B(06990)“买入”评级 指其与MNC合作临床打开海外商业化空间
【券商聚焦】国联证券首予科伦博泰生物-B(06990)“买入”评级 指其多款潜力产品即将步入商业化兑现期
金吾财讯 · 06-21
【券商聚焦】国联证券首予科伦博泰生物-B(06990)“买入”评级 指其多款潜力产品即将步入商业化兑现期
科伦博泰生物-B(06990.HK):ADC管线厚积薄发的平台型创新药企
国联证券 · 06-21
科伦博泰生物-B(06990.HK):ADC管线厚积薄发的平台型创新药企
暂无数据
公司概况
公司名称:
科伦博泰生物-B
所属市场:
SEHK
上市日期:
--
主营业务:
四川科伦博泰生物医药股份有限公司是一家主要从事创新药业务的研发、生产和销售的中国公司。该公司主要从事生物药品、化学药品原料、化学药品制剂的研发、生产和销售。该公司的产品主要用于乳腺癌、非小细胞肺癌、胃肠道癌等非肿瘤疾病的治疗。
发行价格:
--
{"stockData":{"symbol":"06990","market":"HK","secType":"STK","nameCN":"科伦博泰生物-B","latestPrice":163.4,"timestamp":1720166887020,"preClose":151.9,"halted":0,"volume":357955,"delay":0,"floatShares":130273005,"shares":222844099,"eps":-3.0438344,"marketStatus":"休市中","marketStatusCode":7,"change":11.5,"latestTime":"07-05 16:08:07","open":157.7,"high":163.9,"low":149.7,"amount":56659173,"amplitude":0.093483,"askPrice":163.4,"askSize":1100,"bidPrice":161,"bidSize":700,"shortable":3,"etf":0,"ttmEps":-3.043834479406482,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1720402200000},"adr":0,"listingDate":1689004800000,"adjPreClose":151.9,"openAndCloseTimeList":[[1720143000000,1720152000000],[1720155600000,1720166400000]],"volumeRatio":1.3338592435647156,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06990/tweets","defaultTab":"tweets","newsList":[{"id":"2449264633","title":"科伦博泰生物-B(06990):认购结构性存款","url":"https://stock-news.laohu8.com/highlight/detail?id=2449264633","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449264633?lang=zh_cn&edition=full","pubTime":"2024-07-05 20:37","pubTimestamp":1720183044,"startTime":"0","endTime":"0","summary":"智通财经APP讯,科伦博泰生物-B(06990)发布公告,于2024年4月22日及2024年7月5日,公司分别订立交通银行结构性存款协议I及交通银行结构性存款协议II,据此,公司同意向交通银行分别认购本金额为人民币1.70亿元及人民币2亿元的两笔结构性存款。于本公告日期,向交通银行收购的结构性存款未偿还本金总额为人民币3.70亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1146466.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","06990"],"gpt_icon":0},{"id":"2449255701","title":"港股收盘(07.05) | 恒指收跌1.27% 科技股、汽车股普遍承压 医药股午后拉升","url":"https://stock-news.laohu8.com/highlight/detail?id=2449255701","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449255701?lang=zh_cn&edition=full","pubTime":"2024-07-05 16:40","pubTimestamp":1720168856,"startTime":"0","endTime":"0","summary":"截止收盘,恒生指数跌1.27%或228.67点,报17799.61点,全日成交额903.21亿港元;恒生国企指数跌1.37%,报6382.27点;恒生科技指数跌1.45%,报3596.8点。蓝筹股表现康师傅控股创9个月新高。截至收盘,涨1.6%,报10.18港元,成交额1.99亿港元,贡献恒指0.52点。热门异动股1. 中国中免全天活跃,截至收盘,涨3.82%,报54.35港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1146124.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0417516902.SGD","LU1720050803.USD","BK1539","07226","HHImain","HSI","BK1161","09939","BK1574","513600","BK1147","03086","BK1198","BK1592","00863","BK1224","LU0229945570.USD","HSCEI","LU0417516738.SGD","BK1515","159938","06990","LU0348825331.USD","MCHmain","HSTECH","03330","BK1119","LU0543330566.HKD","02545","TTTN","02833","BK1544","01114","LU0348735423.USD","LU1794554557.SGD","BK1131","YANG","01880"],"gpt_icon":0},{"id":"2449023084","title":"港股异动 | 科伦博泰生物-B(06990)现涨超7% 公司携手默沙东出海 机构称核心产品商业化在即","url":"https://stock-news.laohu8.com/highlight/detail?id=2449023084","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449023084?lang=zh_cn&edition=full","pubTime":"2024-07-05 15:49","pubTimestamp":1720165766,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,科伦博泰生物-B现涨超7%,截至发稿,涨7.44%,报163.2港元,成交额5533.85万港元。2022年5月至12月,科伦博泰生物与默沙东共达成3笔合作交易,覆盖9款ADC新药,总预付款2.57亿美元,总交易金额高达118亿美元。默沙东的Keytruda和ADC具备极佳的联用潜质。ADC和PD-1强强联合有望为科伦博泰带来不菲的海外收入提成。值得注意的是,科伦博泰有4-5个管线即将商业化,其中包括两项核心ADC产品SKB264和A166,有望在2027年扭亏为盈。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1146067.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["MRK","HSCEI","IE0002141913.USD","07226","LU0208291251.USD","LU1917777945.USD","SG9999014542.SGD","LU2361045086.USD","SG9999013999.USD","SG9999001440.SGD","IE00BFTCPJ56.SGD","LU0211331839.USD","LU2106854487.HKD","IE00BSNM7G36.USD","LU1974910355.USD","IE00BJJMRZ35.SGD","BK4559","SG9999002232.USD","LU0234572021.USD","LU0985320562.USD","YANG","SG9999002224.SGD","LU0861579265.USD","06990","SG9999014559.SGD","IE0009355771.USD","LU1291159041.SGD","BK4588","BK4007","LU2361044865.SGD","LU2461242641.AUD","LU0289739699.SGD","LU1093756325.SGD","LU0070302665.USD","IE00B2B36J28.USD","LU2023250504.SGD","LU0965509101.SGD","BK4516","BK4550","LU0238689110.USD","BK4533","IE00BLSP4452.SGD","HSTECH","LU0320765489.SGD","LU0965509010.AUD","BK4534","LU1430594728.SGD","SG9999014567.USD","LU0266013472.USD","LU1066053197.SGD"],"gpt_icon":0},{"id":"2449286652","title":"“体重管理年”实施方案出台,港股创新药ETF(159567)跟踪指数拉升翻红,泰格医药、绿叶制药、科伦博泰生物-B领涨。","url":"https://stock-news.laohu8.com/highlight/detail?id=2449286652","media":"界面有连云","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449286652?lang=zh_cn&edition=full","pubTime":"2024-07-05 10:18","pubTimestamp":1720145887,"startTime":"0","endTime":"0","summary":"2024年7月5日,港股创新药板块趋势上行。首创证券表示,6月26日,国家卫生健康委等16个部门联合制定了《“体重管理年”活动实施方案》。当前我国超重和肥胖人群占比较高,形势不容乐观,随着16个部门联合出台《“体重管理年”活动实施方案》,同时叠加司美格鲁肽注射液在国内获批减肥适应症,减肥药上下游产业链或再将迎来投资机会。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024070510494795795276&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024070510494795795276&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1141","BK1191","02186","BK1583","06990","BK1606","BK1576","03347","BK1161"],"gpt_icon":0},{"id":"2449400175","title":"科伦博泰生物-B(06990)上涨5.07%,报159.6元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2449400175","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449400175?lang=zh_cn&edition=full","pubTime":"2024-07-05 09:50","pubTimestamp":1720144227,"startTime":"0","endTime":"0","summary":"7月5日,科伦博泰生物-B(06990)盘中上涨5.07%,截至09:50,报159.6元/股,成交992.96万元。四川科伦博泰生物医药股份有限公司是一家专注于创新药物研发、制造及商业化的生物医药公司,主要致力于内部开发差异化的治疗方法,以支持提高现有的医疗健康水平。公司已建立涵盖全部主要药物开发功能的一体化能力,能够战略性地快速推进33款差异化且具有临床价值的资产管线,其中14款处于临床阶段,并已签署了九项对外许可协议,前期及里程碑付款合共高达118亿美元。截至2023年年报,科伦博泰生物-B营业总收入15.4亿元、净利润-5.74亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/07/05095041389547.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1161","06990"],"gpt_icon":0},{"id":"2449288928","title":"科伦博泰生物-B(06990)股价上升5.003%,现价港币$159.5","url":"https://stock-news.laohu8.com/highlight/detail?id=2449288928","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449288928?lang=zh_cn&edition=full","pubTime":"2024-07-05 09:50","pubTimestamp":1720144200,"startTime":"0","endTime":"0","summary":"[上升股]科伦博泰生物-B(06990) 股价在上午09:50比前收市价上升5.003%,现股价为港币$159.5。至目前为止,今日最高价为$159.5,而最低价为$150.8。总成交量为6.22万股,总成交金额为港币$970.631万。","market":"other","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180112133337750_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180112133337750_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR240705185/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","06990"],"gpt_icon":0},{"id":"2448414988","title":"科伦博泰生物-B07月04日获主力加仓482万元 环比增加760.71%","url":"https://stock-news.laohu8.com/highlight/detail?id=2448414988","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448414988?lang=zh_cn&edition=full","pubTime":"2024-07-04 16:16","pubTimestamp":1720081000,"startTime":"0","endTime":"0","summary":"07月04日, 科伦博泰生物-B股价跌2.25%,报收151.90元,成交金额3077万元,换手率0.15%,振幅7.01%,量比0.83。科伦博泰生物-B今日主力资金净流入482万元,上一交易日主力净流入56万元,今日环比增加760.71%。该股近5个交易日下跌8.83%,主力资金累计净流入391万元,其中1个交易日为股价上涨时净流出;近20日主力资金累计净流入406万元,其中净流入天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407041617129573d59c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407041617129573d59c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","06990"],"gpt_icon":0},{"id":"2448438671","title":"科伦博泰生物-B(06990)下跌5.06%,报150.0元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2448438671","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448438671?lang=zh_cn&edition=full","pubTime":"2024-07-03 09:52","pubTimestamp":1719971520,"startTime":"0","endTime":"0","summary":"7月3日,科伦博泰生物-B(06990)盘中下跌5.06%,截至09:52,报150.0元/股,成交353.57万元。四川科伦博泰生物医药股份有限公司是一家专注于创新药物研发、制造及商业化的生物医药公司,主要致力于内部开发差异化的治疗方法,以支持提高现有的医疗健康水平。公司已建立涵盖全部主要药物开发功能的一体化能力,能够战略性地快速推进33款差异化且具有临床价值的资产管线,其中14款处于临床阶段,并已签署了九项对外许可协议,前期及里程碑付款合共高达118亿美元。截至2023年年报,科伦博泰生物-B营业总收入15.4亿元、净利润-5.74亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/07/03095241341551.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1161","06990"],"gpt_icon":0},{"id":"2448397986","title":"科伦博泰生物-B(06990)下跌5.85%,报156.1元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2448397986","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448397986?lang=zh_cn&edition=full","pubTime":"2024-07-02 09:38","pubTimestamp":1719884335,"startTime":"0","endTime":"0","summary":"7月2日,科伦博泰生物-B(06990)盘中下跌5.85%,截至09:38,报156.1元/股,成交421.5万元。四川科伦博泰生物医药股份有限公司是一家专注于创新药物研发、制造及商业化的生物医药公司,主要致力于内部开发差异化的治疗方法,以支持提高现有的医疗健康水平。公司已建立涵盖全部主要药物开发功能的一体化能力,能够战略性地快速推进33款差异化且具有临床价值的资产管线,其中14款处于临床阶段,并已签署了九项对外许可协议,前期及里程碑付款合共高达118亿美元。截至2023年年报,科伦博泰生物-B营业总收入15.4亿元、净利润-5.74亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407020940429ef0d4a9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407020940429ef0d4a9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","06990"],"gpt_icon":0},{"id":"2446688495","title":"科伦博泰生物-B(06990)拟以624万元向科伦药业(002422.SZ)附属收购一系列设备","url":"https://stock-news.laohu8.com/highlight/detail?id=2446688495","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446688495?lang=zh_cn&edition=full","pubTime":"2024-06-28 21:41","pubTimestamp":1719582070,"startTime":"0","endTime":"0","summary":"智通财经APP讯,科伦博泰生物-B 发布公告,于2024年6月28日,公司与科伦药业的全资附属公司科伦精准订立设备采购协议,据此,公司同意采购而科伦精准同意出售设备,代价为人民币624万元。科伦精准出售设备为集团的采购提供了一个恰当时机,且集团已采购大量实验室及桌面设备,用于加强现有研发能力及改善日常营运效率。此外,集团在采购、安装及测试设备过程中将受益于科伦精准的专业知识及资源。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1142995.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0060","LU2148510915.USD","BK0239","LU1064130708.USD","06990","BK1161","002422","LU1064131003.USD"],"gpt_icon":0},{"id":"2446528073","title":"科伦博泰生物-B(06990)下跌5.19%,报151.5元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2446528073","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446528073?lang=zh_cn&edition=full","pubTime":"2024-06-28 14:17","pubTimestamp":1719555420,"startTime":"0","endTime":"0","summary":"6月28日,科伦博泰生物-B(06990)盘中下跌5.19%,截至14:17,报151.5元/股,成交2517.44万元。四川科伦博泰生物医药股份有限公司是一家专注于创新药物研发、制造及商业化的生物医药公司,主要致力于内部开发差异化的治疗方法,以支持提高现有的医疗健康水平。公司已建立涵盖全部主要药物开发功能的一体化能力,能够战略性地快速推进33款差异化且具有临床价值的资产管线,其中14款处于临床阶段,并已签署了九项对外许可协议,前期及里程碑付款合共高达118亿美元。截至2023年年报,科伦博泰生物-B营业总收入15.4亿元、净利润-5.74亿元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/06/28141741256381.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["06990","BK1161"],"gpt_icon":0},{"id":"2446537750","title":"科伦博泰生物-B(06990.HK)认购1亿元理财产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2446537750","media":"格隆汇资讯","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446537750?lang=zh_cn&edition=full","pubTime":"2024-06-27 21:06","pubTimestamp":1719493607,"startTime":"0","endTime":"0","summary":"格隆汇6月27日丨科伦博泰生物-B(06990.HK)公告,于2024年6月27日,公司订立兴业银行结构性存款协议,据此,公司同意向兴业银行认购本金额为人民币1亿元的结构性存款。于本公告日期,向兴业银行购买的理财产品的尚未赎回本金总额为人民币2.2亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406272106549f6c028f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406272106549f6c028f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06990","BK1161"],"gpt_icon":0},{"id":"2446373925","title":"科伦博泰生物-B(06990)合共认购2.2亿元兴业银行理财产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2446373925","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446373925?lang=zh_cn&edition=full","pubTime":"2024-06-27 21:02","pubTimestamp":1719493339,"startTime":"0","endTime":"0","summary":"智通财经APP讯,科伦博泰生物-B(06990)公布,于2023年5月18日及2023年5月24日(于上市日期前),公司分别认购由兴业银行发行的两份大额可转让存单,本金额分别为人民币7000万元及人民币5000万元。于2024年6月27日,公司订立兴业银行结构性存款协议,据此,公司同意向兴业银行认购本金额为人民币1亿元的结构性存款。于本公告日期,向兴业银行购买的理财产品的尚未赎回本金总额为人民币2.2亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1141953.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["601166","LU0572940350.SGD","LU1781817850.SGD","BK0278","LU1048596156.SGD","LU0821914370.USD","06990","BK0015","BK0028","BK0183","BK1161","LU1328615791.USD","BK0187","BK0012","BK0188","LU1580142542.USD","LU0572939691.SGD","LU0264606111.USD"],"gpt_icon":0},{"id":"2446376722","title":"科伦博泰生物-B(06990)下跌5.17%,报157.9元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2446376722","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446376722?lang=zh_cn&edition=full","pubTime":"2024-06-27 11:22","pubTimestamp":1719458529,"startTime":"0","endTime":"0","summary":"6月27日,科伦博泰生物-B(06990)盘中下跌5.17%,截至11:22,报157.9元/股,成交354.48万元。四川科伦博泰生物医药股份有限公司是一家专注于创新药物研发、制造及商业化的生物医药公司,主要致力于内部开发差异化的治疗方法,以支持提高现有的医疗健康水平。公司已建立涵盖全部主要药物开发功能的一体化能力,能够战略性地快速推进33款差异化且具有临床价值的资产管线,其中14款处于临床阶段,并已签署了九项对外许可协议,前期及里程碑付款合共高达118亿美元。截至2023年年报,科伦博泰生物-B营业总收入15.4亿元、净利润-5.74亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/06/27112241230486.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1161","06990"],"gpt_icon":0},{"id":"2446896385","title":"科伦博泰生物-B(06990)下跌5.26%,报162.0元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2446896385","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446896385?lang=zh_cn&edition=full","pubTime":"2024-06-25 15:58","pubTimestamp":1719302283,"startTime":"0","endTime":"0","summary":"6月25日,科伦博泰生物-B(06990)盘中下跌5.26%,截至15:58,报162.0元/股,成交1798.53万元。四川科伦博泰生物医药股份有限公司是一家专注于创新药物研发、制造及商业化的生物医药公司,主要致力于内部开发差异化的治疗方法,以支持提高现有的医疗健康水平。公司已建立涵盖全部主要药物开发功能的一体化能力,能够战略性地快速推进33款差异化且具有临床价值的资产管线,其中14款处于临床阶段,并已签署了九项对外许可协议,前期及里程碑付款合共高达118亿美元。截至2023年年报,科伦博泰生物-B营业总收入15.4亿元、净利润-5.74亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/06/25155841181832.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1161","06990"],"gpt_icon":0},{"id":"2445025350","title":"科伦博泰生物-B(06990)ADC征途星辰大海,携手跨国龙头进军国际市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2445025350","media":"国盛证券","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445025350?lang=zh_cn&edition=full","pubTime":"2024-06-24 17:16","pubTimestamp":1719220596,"startTime":"0","endTime":"0","summary":"科伦博泰深耕ADC创新分子研发十余年,是国内首批及全球少数建立集成ADC开发平台的公司之一。OptiDC平台基于多样化的ADC核心元件库,已通过十多项临床或临床前候选药物验证、实现超过2000例患者入组。A166:潜在第2款国产HER2ADC,有望在乳腺癌领域取得突破,预计2024年内获批上市。公司已先后与跨国龙头药企默沙东达成3笔重磅合作授权,交易总金额近118亿美元,成为首个向国际前十MNC输出自研ADC的国内企业。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406241730349f5f443d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406241730349f5f443d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06990","BK1161"],"gpt_icon":0},{"id":"2445782417","title":"【券商聚焦】华泰证券首予科伦博泰生物-B(06990)“买入”评级 指其与MNC合作临床打开海外商业化空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2445782417","media":"金吾财讯","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445782417?lang=zh_cn&edition=full","pubTime":"2024-06-21 15:35","pubTimestamp":1718955336,"startTime":"0","endTime":"0","summary":"金吾财讯 | 华泰证券发研报指,科伦博泰生物-B 为科伦药业控股创新药子公司平台,公司2016年成立至今已深度搭建大&小分子及OptiDCADC三大研发平台,14款临床产品中 5款已进入关键试验/NDA阶段。基于公司:1)重磅ADC管线;2)前瞻性布局免疫/肿瘤靶向大分子,与公司 ADC联用剑指一线治疗方案;3)与MNC合作临床,打开海外商业化空间。","market":"fut","thumbnail":"https://static.szfiu.com/news/20210810/ZGJmMjQzMjRiY2NiODcyOGI4M2QwNmEzMTRlMzQwNzE0NzI4MDg4Ng==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/ZGJmMjQzMjRiY2NiODcyOGI4M2QwNmEzMTRlMzQwNzE0NzI4MDg4Ng==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1939100","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"gpt_icon":0},{"id":"2445781515","title":"【券商聚焦】国联证券首予科伦博泰生物-B(06990)“买入”评级 指其多款潜力产品即将步入商业化兑现期","url":"https://stock-news.laohu8.com/highlight/detail?id=2445781515","media":"金吾财讯","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445781515?lang=zh_cn&edition=full","pubTime":"2024-06-21 14:54","pubTimestamp":1718952853,"startTime":"0","endTime":"0","summary":"金吾财讯 | 国联证券发研报指,科伦博泰生物-B 作为实力雄厚的ADC平台型创新药企,管线价值获默沙东高度认可,SKB-264最高总交易金额达14亿美元,7个在研ADC项目最高总交易金额近 95亿美元。SKB-264、A166以及A140等产品均即将进入商业兑现期。SKB-264有望于2024年中国获批上市用于治疗三阴性乳腺癌,后续泛瘤种适应症拓展将持续贡献销售增量。KL-A166有望于2024年中国获批上市并成为首个在HER2阳性乳腺癌获批的国产 ADC。","market":"sh","thumbnail":"https://static.szfiu.com/news/20210810/NGI5ZWE4NDg5Y2ExYTk3MGU2NzMxODA4MzkxNTM=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NGI5ZWE4NDg5Y2ExYTk3MGU2NzMxODA4MzkxNTM=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1939092","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["601456","01456","06990"],"gpt_icon":0},{"id":"2445273481","title":"科伦博泰生物-B(06990.HK):ADC管线厚积薄发的平台型创新药企","url":"https://stock-news.laohu8.com/highlight/detail?id=2445273481","media":"国联证券","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445273481?lang=zh_cn&edition=full","pubTime":"2024-06-21 07:31","pubTimestamp":1718926299,"startTime":"0","endTime":"0","summary":"投资要点:管线价值广阔并即将兑现的ADC 前沿创新药企公司作为实力雄厚的ADC 平台型创新药企,管线价值获默沙东高度认可,SKB-264 最高总交易金额达14 亿美元,7 个在研ADC 项目最高总交易金额近95 亿美元。SKB-264、A166 以及A140 等产品均即将进入商业兑现期。SKB-264 有望于2024 年中国获批上市用于治疗三阴性乳腺癌,后续泛瘤种适应症拓展将持续贡献销售增量。KL-A166 有望于2024 年中国获批上市并成为首个在HER2阳性乳腺癌获批的国产ADC。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062107314395c72b26&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062107314395c72b26&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","06978","06990","BK1161"],"gpt_icon":0}],"profile":{"websiteUrl":"http://kelun-biotech.com","stockEarnings":[{"period":"1week","weight":-0.0145},{"period":"1month","weight":-0.0987},{"period":"3month","weight":0.1815},{"period":"6month","weight":0.602},{"period":"1year","weight":1.6964},{"period":"ytd","weight":0.5879}],"compareEarnings":[{"period":"1week","weight":0.0046},{"period":"1month","weight":-0.0339},{"period":"3month","weight":0.0643},{"period":"6month","weight":0.0765},{"period":"1year","weight":-0.0396},{"period":"ytd","weight":0.0441}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"四川科伦博泰生物医药股份有限公司是一家主要从事创新药业务的研发、生产和销售的中国公司。该公司主要从事生物药品、化学药品原料、化学药品制剂的研发、生产和销售。该公司的产品主要用于乳腺癌、非小细胞肺癌、胃肠道癌等非肿瘤疾病的治疗。","exchange":"SEHK","name":"科伦博泰生物-B","nameEN":"SKB BIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"科伦博泰生物-B(06990)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供科伦博泰生物-B(06990)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"科伦博泰生物-B,06990,科伦博泰生物-B股票,科伦博泰生物-B股票老虎,科伦博泰生物-B股票老虎国际,科伦博泰生物-B行情,科伦博泰生物-B股票行情,科伦博泰生物-B股价,科伦博泰生物-B股市,科伦博泰生物-B股票价格,科伦博泰生物-B股票交易,科伦博泰生物-B股票购买,科伦博泰生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"科伦博泰生物-B(06990)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供科伦博泰生物-B(06990)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}